FDA Approves Opdivo (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma Regardless of PD-L1 Expression Status

PRINCETON, N.J.--(BUSINESS WIRE)-- April 16, 2021 Opdivo is the first and only immunotherapy in combination with chemotherapy to deliver superior overall survival versus chemotherapy alone in a trial of this patient population1 U.S. Food and...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news

Related Links:

We report an unusual case of an EBV-associated foveolar gastric dysplasia associated with a focus of EBV-positive low-grade tubular adenocarcinoma, arisen in the context of a lymphocytic-like (EBV-positive) gastritis. The present case offers the unique opportunity to determine whether EBV is an early or late event in gastric cancer development and to evaluate its prevalence in patients with gastric dysplasia. To properly address this question, we investigated EBER expression in a large mono-institutional series of gastric and gastro-esophageal cancers (n = 594) and associated precursor lesions (n =&thi...
Source: Virchows Archiv - Category: Pathology Source Type: research
Conclusion: According to this study, a significant increase was observed in the incidence of cancers in the north and western regions of Iran. Hence, screening and early detection programs are highly recommended in these high-risk areas.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
Cancers, Vol. 13, Pages 4591: Combined Therapy of Locally Advanced Oesophageal and Gastro–Oesophageal Junction Adenocarcinomas: State of the Art and Aspects of Predictive Factors Cancers doi: 10.3390/cancers13184591 Authors: Milan Vošmik Jindřich Kopecký Stanislav John Ondřej Kubeček Petr Lochman Aml Mustafa Banni Libor Hruška Igor Sirák The following main treatment approaches are currently used in locally advanced adenocarcinomas of the oesophagus and gastrooesophageal junction (GOJ): preoperative chemoradiotherapy and surgery, and perioperative chemotherapy and s...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Conditions:   Advanced Gastric Adenocarcinoma;   Advanced Gastroesophageal Junction Adenocarcinoma;   Clinical Stage III Gastric Cancer AJCC v8;   Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IV Gastric Cancer AJCC v8;   Clinical Stage IV Gastroes ophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVA Gastric Cancer AJCC v8;   Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage&n...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Clinical Stage IV Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage IV Gastric Cancer AJCC v8;   Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8;   C linical Stage IVA Gastric Cancer AJCC v8;   Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8;   Clinical Stage IVB Gastric Cancer A...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This article reviews recent randomised clinical trials on systemic treatment of oesophago-gastric cancers in the perioperative and metastatic setting. Recent findings Adding nivolumab to first-line chemotherapy improved survival in patients with metastatic gastric/gastro-oesophageal junction/oesophageal adenocarcinoma with PD-L1 combined positive score (CPS) ≥ five in a global trial and progression-free survival in metastatic gastric/gastro-oesophageal junction cancers in an Asian trial. The addition of pembrolizumab to first-line chemotherapy improved survival in metastatic oesophageal cancer patients, with the ...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: GASTROINTESTINAL TRACT: Edited by Alain Hendlisz and Francesco Sclafani Source Type: research
SummaryDuring this year ’s virtual congress of the European Society of Oncology (ESMO) some practice-changing abstracts were presented. Especially immunotherapy (IO) has found its way into the treatment of esophageal (EC) and gastric cancer (GC) in both the adjuvant and palliative setting. The CheckMate 577 trial, which was presented in EMSO Presidential Symposium III, showed a doubling in disease-free survival (DFS) for patients with resected esophageal (EC) or esophagogastric junction cancer (EGJC) following neoadjuvant chemoradiation therapy (CRT), who had not achieved a pathological complete respon...
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION: Overall, pembrolizumab was safe and had limited antitumor activity in these patients. In the advanced, metastatic setting, tumor profiling to understand the mechanisms of resistance to immunotherapy and innovative clinical trials to identify efficacious combination regimens rather than off-label use of pembrolizumab are warranted. DISCUSSION: Germ cell tumors are associated with a diverse histopathology and clinical prognosis. Approximately 20%-30% of patients with metastatic germ cell tumors have disease resistant to standard chemotherapy [1], and 15%-20% of these tumors are incurable with the available t...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Background: Perioperative chemotherapy plus surgery is one recommended standard treatment for patients with resectable gastric and esophageal cancer. Even with a multimodality treatment more than half of patients will relapse following surgical resection. Patients who have a poor response to neoadjuvant chemotherapy and have an incomplete (R1) resection or have metastatic lymph nodes in the resection specimen (N+) are especially at risk of recurrence. Current clinical practice is to continue with the same chemotherapy in the adjuvant setting as before surgery. In the phase II randomized EORTC VESTIGE trial (NCT03443856), p...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study aimed to investigate whether combining anti-PD-L1 Atezolizumab with BEV may have a synergistic effect and enhance the efficacy of both treatments in cisplatin resistant epithelial ovarian cancer (CREOC). We retrospectively analyzed 124 epithelial ovarian cancer (EOC) patients from Gynecologic Oncology Department of Tianjin Cancer Hospital between January 2013 and June 2018, who all were diagnosed with cisplatin resistance due to progressing
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | Immunotherapy